ORAL-NICOTINE-COMMISSION
6.12.2022 08:03:40 CET | Business Wire | Press release
Swedish authorities officially confirmed that the current level of smoking in Sweden has fallen to 5,6%. This makes Swedes the only European nation close to reaching the smoke-free goal set by the EU 18 years ahead of the 2040 target.
In an event organised by the Oral Nicotine Commission in Stockholm, participants took stock of Sweden’s incredible achievements and leadership in the race to end smoking. It is about to become the first country in the world to be defined as “smoke free”, representing a share of less than 5% of the population smoking.
Sweden’s smoking rates have shot down since the 1980s from 35% down to below 6% - a feat that is yet to be replicated by any other nation in the world. The next lowest smoking rate in Europe is double that of Sweden’s, with the EU average sitting somewhere around 23%, four times higher than in Sweden. The result is the lowest tobacco mortality rate in Europe.
A group of leading public health professionals, consumer advocates and harm reduction experts that met to celebrate the achievement on 30 November 2022 in Stockholm have reaffirmed their call to policymakers around the world to ensure that less harmful alternatives to smoking are available to support smokers to quit.
Commenting at the event, Dr. Delon Human, President of Health Diplomats and organiser of the event in Stockholm said: “If all smokers in the world, some 1.1 billion people, would switch to one of less harmful alternative smoke-free, nicotine-based products, it could prevent disease and save millions of lives worldwide. Sweden has found the fire-escape for smokers. We need to work together to repeat the Swedish experience globally to save lives.”
This incredible success story gave attendees the chance to better understand Sweden’s recipe to success, key to which is its openness to less harmful alternatives to smoking. Snus has been at the forefront of the reduction measures, but in recent years, nicotine pouches and e-cigarettes have become another valuable tool for Swedish smokers aiming to quit.
The progressive, pro harm-reduction Swedish model is clearly distinct from the policies proposed by international organisations in favour of tobacco control. At an EU level, harm reduction advocates have fought hard to have harm reduction recognised in the European Beating Cancer Plan. The WHO still refuses to acknowledge its value, despite the fact that harm reduction is explicitly recognised in the Framework Convention for Tobacco Control.
Commenting at the event, Professor Karl Fagerström said: “The upcoming Swedish EU presidency is a great opportunity to share their 5% success story to other EU countries. We hope that Sweden will be generous with sharing this know-how internationally.”
Speakers at the conference emphasised the need for sound evidence-based policy interventions in tobacco control. This translates to the broad adoption of tobacco harm reduction policies that support a journey to quitting smoking.
Ensuring that less harmful alternatives to smoking are affordable, accessible and affordable will be paramount to ensure that other countries can replicate Sweden’s success. This event is the start of much needed discussion of this topic.
The Oral Nicotine Commission is a global not-for-profit association that helps build the evidence base and raise awareness of Oral Nicotine among both governments, public health leaders and the public, thus countering negative, unfounded preconceptions and stereotypes. It addresses policy, science, consumer issues and relevant product innovations. Its views are independent of any brand or manufacturer and focuses on the individual and population health needs of adult smokers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005671/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
